Every Form 4 that Zentalis Pharmaceuticals, Inc. (ZNTL) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow ZNTL and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ZNTL filings page.
Zentalis Pharmaceuticals, Inc. (ZNTL) reported that The Walters Group, a ten percent owner, purchased 4,335,000 shares of common stock in an open-market or private transaction at $3.50 per share on August 14, 2026. Following this purchase, The Walters Group directly holds 17,844,973 shares. William T. Walters and Susan B. Walters may be deemed to share voting and dispositive power over these shares but each reporting person disclaims Section 16 beneficial ownership except to the extent of any pecuniary interest.
Johnson David Michael reported acquisition or exercise transactions in this Form 4 filing.
Zentalis Pharmaceuticals director David Michael Johnson received an equity award rather than making an open-market trade. He was granted 57,100 restricted stock units under the company’s Non-Employee Director Compensation Program, each representing one share of common stock at no cash cost to him.
The units will vest on the earlier of June 16, 2027 or the next annual stockholder meeting, as long as he continues serving on the board through that date. Following this award, Johnson directly holds 307,521 shares of Zentalis common stock.
Skvarka Jan reported acquisition or exercise transactions in this Form 4 filing.
Zentalis Pharmaceuticals director Jan Skvarka received 57,100 restricted stock units as equity compensation. The grant was made at no cash cost and will vest on the earlier of June 16, 2027 or the next annual stockholder meeting, subject to continued board service. Following this award, Skvarka holds 264,254 shares/units of common stock.
Walker Luke Nathaniel reported acquisition or exercise transactions in this Form 4 filing.
Zentalis Pharmaceuticals director Luke Nathaniel Walker received an equity award of 57,100 shares of common stock in the form of restricted stock units. These units were granted at no cash cost and increase his direct holdings to 201,384 shares of common stock.
The restricted stock units each represent a contingent right to receive one share of common stock. They will vest on the earlier of June 16, 2027 or the next annual meeting of stockholders, provided Walker continues to serve on the board through the vesting date. This is a compensation-related grant rather than an open-market purchase.
Kariuki Enoch reported acquisition or exercise transactions in this Form 4 filing.
Zentalis Pharmaceuticals director Enoch Kariuki received an equity award in the form of restricted stock units. The grant covers 57,100 RSUs, each representing one share of common stock at no purchase price. After this award, he directly holds 194,465 shares. The RSUs vest on the earlier of June 16, 2027 or the next annual stockholder meeting, if he continues serving on the board.
Myers Scott Dunseth reported acquisition or exercise transactions in this Form 4 filing.
Zentalis Pharmaceuticals director Scott Dunseth Myers received a grant of 57,100 restricted stock units (RSUs). The award was made at no cash cost and increases his direct holdings to 395,895 shares of common stock. The RSUs vest on the earlier of June 16, 2027 or the next annual stockholder meeting, subject to his continued board service.
Campbell Shannon reported acquisition or exercise transactions in this Form 4 filing.
Zentalis Pharmaceuticals director Shannon Campbell received an equity grant in the form of restricted stock units. The award covers 114,200 shares of common stock at no purchase price, granted under the company’s Non-Employee Director Compensation Program. One third of the RSUs will vest on each of the first, second and third anniversaries of the grant date, contingent on continued board service, resulting in 114,200 shares reported as directly owned after this grant.
Zentalis Pharmaceuticals chief medical officer Ingmar Bruns reported automatic sales of company common stock to cover tax withholding on vested restricted stock units. On February 6, 2026, 2,962 shares were sold at $2.4297 per share, followed by 335 shares at $2.3929 per share on February 9, 2026. After these transactions, Bruns beneficially owned 33,332 shares of Zentalis common stock directly.
Zentalis Pharmaceuticals officer Vincent Vultaggio, who serves as PAO and PFO, reported several sales of company common stock. On February 6, 2026, he sold 29,951 shares at $2.4297 per share. On February 9, 2026, he sold 3,379 shares at $2.3929 per share, and on February 10, 2026, he sold 6,894 shares at $2.4223 per share. A footnote explains the first sale was made automatically by the company to cover tax withholding on vesting restricted stock units, while the later sale was executed under a pre-established Rule 10b5-1 trading plan. After these transactions, Vultaggio directly held 146,506 shares of Zentalis common stock.
Zentalis Pharmaceuticals, Inc. reported an insider transaction by its CEO & President and director, Julia Marie Eastland. On February 6, 2026, 7,866 shares of common stock were sold at $2.4297 per share, leaving 80,022 shares owned directly. On February 9, 2026, a further 889 shares were sold at $2.3929 per share, leaving 79,133 shares owned directly.
According to the footnote, these sales were made automatically by the issuer to cover tax withholding obligations arising from the vesting and settlement of restricted stock units previously granted to Eastland, rather than discretionary open-market sales.
Zentalis Pharmaceuticals officer Vincent Vultaggio reported two sales of common stock. On February 2, 2026, he sold 2,540 shares at $2.55 per share, an automatic sale by the company to cover tax withholding on vested restricted stock units.
On February 3, 2026, he sold 556 shares at $2.515 per share under a pre-arranged Rule 10b5-1 trading plan. After these transactions, he beneficially owned 186,730 shares of Zentalis common stock in direct form.
Zentalis Pharmaceuticals, Inc. reported that officer Vincent Vultaggio received a stock option grant for 100,000 shares on January 8, 2026. The options have an exercise price of $2.84 per share and expire on January 7, 2036. Following this grant, he beneficially owns 100,000 stock options directly.
According to the footnote, the options vest over four years in substantially equal monthly installments, and vesting depends on his continued service with the company. This structure ties the long-term value of the award to his ongoing tenure and the company’s future performance.
Zentalis Pharmaceuticals reported an equity award to its Chief Legal Officer, James B. Bucher. He received a stock option grant covering 100,000 shares of common stock at an exercise price of $2.84 per share. The options were granted on January 8, 2026 and are held directly. Following this grant, Bucher beneficially owns 100,000 stock options.
The options will vest over four years in substantially equal monthly installments, and vesting is conditioned on his continued service with the company. This is a compensatory award rather than an open-market purchase or sale.
Zentalis Pharmaceuticals, Inc. reported that its Chief Medical Officer, Ingmar Bruns, received a grant of stock options on 01/08/2026. The award covers 365,000 stock options with an exercise price of $2.84 per share and an expiration date of 01/07/2036. Each option is exercisable for one share of common stock, giving potential access to 365,000 shares if exercised in the future.
According to the filing, the options were granted at a price of $0 for the derivative security itself and are held directly by the reporting person. The options will vest over four years in substantially equal monthly installments, as long as Bruns continues to serve with the company, so ownership rights build gradually rather than all at once.
Zentalis Pharmaceuticals, Inc. reported an insider equity award for its CEO and President, Julia Marie Eastland, in a Form 4 filing. On January 8, 2026, she received a grant of stock options to buy 775,000 shares of the company’s common stock at an exercise price of $2.84 per share. These options were reported as held directly, with 775,000 derivative securities beneficially owned following the transaction.
According to the filing, the options will vest over four years in substantially equal monthly installments, and vesting is conditioned on her continued service with the company. There were no sales of stock reported; this filing reflects an award of options rather than a disposition of shares.
Zentalis Pharmaceuticals director-affiliated entity The Walters Group purchased 6,459,973 shares of the company’s common stock at $1.20 per share. This transaction on 12/31/2025 increased the entity’s holdings to 13,509,973 shares of Zentalis common stock. The filing identifies The Walters Group as the direct holder of the shares, while William T. Walters and Susan B. Walters may be deemed to share voting and dispositive power through their roles with the entity. Each reporting person disclaims beneficial ownership of the reported shares except to the extent of any pecuniary interest.
Zentalis Pharmaceuticals, Inc. (ZNTL) disclosed a large insider sale by entities affiliated with Matrix Capital Management Company, LP and its managing general partner, David E. Goel. On 12/15/2025, the reporting persons sold 7,500,000 shares of Zentalis common stock at $1.33 per share in an open market or private sale transaction coded "S".
After this transaction, they reported 6,459,973 shares of Zentalis common stock beneficially owned on an indirect basis, held through Matrix Capital Management Master Fund, LP. The reporting persons, including the investment manager and Mr. Goel, expressly disclaim beneficial ownership of these securities except to the extent of their pecuniary interest.